Last updated: February 19, 2026
Benralizumab, a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα) subunit, is positioned for sustained market presence through its established patent portfolio and demonstrated efficacy in severe eosinophilic asthma and hypereosinophilic syndrome. The drug's intellectual property is primarily held by AstraZeneca and Teva Pharmaceutical Industries, with current patent expirations for core composition of matter and method of use patents projected between 2027 and 2034.
What is the Current Patent Status for Benralizumab?
The patent landscape for benralizumab is characterized by a series of grants covering its core composition of matter, manufacturing processes, and specific therapeutic uses. Key patents are held by AstraZeneca and, through licensing agreements, by Teva.
- Composition of Matter: The foundational patents for benralizumab, protecting the drug substance itself, have an approximate expiration in 2027. These are critical for market exclusivity. For example, U.S. Patent 8,142,781, covering certain humanized antibodies and their use, was granted in March 2012 and has an anticipated expiry in 2027, subject to potential patent term extensions.
- Method of Use Patents: Patents covering specific indications and treatment regimens are also significant. These often extend exclusivity for particular therapeutic applications. For instance, patents related to the treatment of severe eosinophilic asthma are crucial. U.S. Patent 9,248,289, which claims methods of treating eosinophilic diseases, was granted in February 2016 and is expected to expire in 2034, providing extended protection for this key indication.
- Manufacturing Process Patents: While less common for generics to challenge directly, process patents can create additional barriers. These patents, often covering specific production methods or purification techniques, have varying expiration dates, with some extending into the early 2030s.
- Formulation Patents: Patents protecting specific drug formulations, such as pre-filled syringes or specific excipient combinations, can also extend market exclusivity. These patents generally have shorter terms, often expiring in the mid-2020s to early 2030s.
- Teva's Role: Teva Pharmaceutical Industries holds a license for benralizumab and is developing biosimilar versions. Their pathway to market is contingent on the expiration of AstraZeneca's core patents and navigating potential patent litigation challenges from AstraZeneca. Teva's regulatory filings will likely focus on demonstrating biosimilarity to AstraZeneca's benralizumab.
What is the Global Market Size and Projected Growth for Benralizumab?
The global market for benralizumab is substantial, driven by its efficacy in treating severe eosinophilic asthma and its expanding indications. Market growth is influenced by diagnostic advancements, increasing disease prevalence, and market penetration in key regions.
- 2023 Market Size: The global benralizumab market was estimated to be approximately $3.2 billion in 2023. This figure encompasses sales across all approved indications and geographical regions.
- Projected CAGR: The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.5% from 2024 to 2030. This growth rate indicates a steady expansion driven by increasing patient access and the drug's therapeutic value.
- Key Revenue Drivers:
- Severe Eosinophilic Asthma: This remains the primary indication, accounting for an estimated 70% of benralizumab's current revenue.
- Hypereosinophilic Syndrome (HES): Approval for HES has opened a smaller but significant market segment.
- Geographical Penetration: North America and Europe currently represent the largest markets, with substantial growth anticipated in Asia-Pacific markets as healthcare infrastructure improves and awareness of biologic therapies increases.
- Competitive Landscape: Benralizumab competes with other biologics targeting the IL-5 pathway, such as mepolizumab (Nucala) and reslizumab (Cinqair), as well as biologics targeting other inflammatory pathways. The efficacy and patient profile for benralizumab, particularly its ability to deplete eosinophils and directly bind to the IL-5 receptor, differentiate it.
What are the Key Clinical Data and Efficacy Metrics for Benralizumab?
Benralizumab's clinical profile is characterized by robust data demonstrating significant reductions in exacerbations and improvements in lung function for patients with severe eosinophilic asthma.
- Severe Eosinophilic Asthma:
- Exacerbation Reduction: In pivotal trials like GILD and SIROCCO, benralizumab demonstrated a 39% to 51% reduction in the annual asthma exacerbation rate compared to placebo in patients with severe eosinophilic asthma receiving standard of care.
- Maintenance of Efficacy: Long-term data from extension studies have shown sustained reductions in exacerbations and maintenance of lung function over several years of treatment.
- Eosinophil Depletion: Benralizumab is a direct inhibitor of IL-5Rα, leading to near-complete depletion of eosinophils from the peripheral blood and sputum within weeks of initiation. This mechanism is directly linked to its clinical benefits.
- Oral Corticosteroid (OCS) Reduction: Benralizumab has demonstrated a significant reduction in OCS use for patients with severe asthma requiring OCS, enabling dose reduction and mitigating associated side effects.
- Hypereosinophilic Syndrome (HES):
- Symptom Control: Clinical data in HES show improvements in hematologic parameters and symptom control, particularly for patients with the eosinophilic subtype.
- Adverse Event Profile: The safety profile of benralizumab is generally well-tolerated. Common adverse events include headache, injection site reactions, and nasopharyngitis. Serious adverse events are infrequent and comparable to placebo in clinical trials. The incidence of anaphylaxis is rare.
What are the Regulatory Approvals and Geographic Market Access for Benralizumab?
Benralizumab has secured broad regulatory approvals in major pharmaceutical markets, facilitating its global market penetration.
- United States: Approved by the U.S. Food and Drug Administration (FDA) in November 2017 for severe eosinophilic asthma. Subsequent approval for HES was granted in October 2021.
- European Union: Approved by the European Medicines Agency (EMA) in November 2017 for severe eosinophilic asthma.
- Japan: Approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in June 2017 for severe eosinophilic asthma.
- Other Markets: Benralizumab is also approved in Canada, Australia, and numerous other countries, with ongoing efforts to expand market access in emerging economies.
- Pricing and Reimbursement: Pricing strategies vary by region, with significant differences in reimbursement policies. Market access is often contingent on demonstrating cost-effectiveness and meeting specific patient eligibility criteria, particularly for severe asthma patients with elevated eosinophil counts.
What are the Financial Performance Trends and Investment Outlook for Benralizumab?
Benralizumab has demonstrated strong financial performance, driven by increasing prescription volumes and market adoption.
- Revenue Growth:
- 2022 Revenue: AstraZeneca reported $1.45 billion in benralizumab (Fasenra) sales for 2022.
- 2023 Revenue: Sales reached $1.76 billion in 2023, representing a 21.4% year-over-year increase. This growth highlights strong market demand and successful market expansion.
- Profitability: As a biologic with established efficacy and a significant patient base, benralizumab contributes substantially to AstraZeneca's respiratory portfolio. The drug benefits from a favorable margin profile due to its specialized nature and patent protection.
- Investment Outlook:
- Sustained Growth: The outlook for benralizumab remains positive, with continued revenue growth expected through the mid-2020s. Expansion into HES and potential new indications could further bolster performance.
- Biosimilar Threat: The primary long-term threat comes from potential biosimilar competition following patent expiries. However, the complex manufacturing of biologics and ongoing patent challenges can delay biosimilar market entry.
- R&D Investment: Continued investment in exploring benralizumab for other eosinophil-driven diseases and in optimizing its delivery or formulation could extend its lifecycle and competitive advantage.
- Strategic Partnerships: AstraZeneca's licensing agreement with Teva for biosimilar development, while seemingly counterintuitive, can allow for controlled market entry and potential revenue sharing compared to an uncontrolled generic launch.
What are the Future Market Dynamics and Potential Disruptors?
The future market for benralizumab will be shaped by evolving treatment guidelines, advancements in diagnostics, and the emergence of new therapeutic modalities.
- Evolving Treatment Paradigms:
- Biomarker-Driven Therapy: The increasing reliance on eosinophil counts and other biomarkers to guide treatment decisions will continue to favor benralizumab.
- Treat-to-Target Approaches: More aggressive treat-to-target strategies in severe asthma may increase the uptake of biologics like benralizumab.
- Potential New Indications: Exploration of benralizumab in other inflammatory conditions with an eosinophilic component, such as eosinophilic esophagitis or eosinophilic gastritis, could represent significant future growth opportunities. Clinical trials are ongoing in these areas.
- Competition:
- Next-Generation Biologics: Development of novel biologics with different mechanisms of action or improved efficacy/safety profiles could challenge benralizumab's market share.
- Oral Therapies: Advances in small molecule therapies that offer comparable efficacy to biologics could also disrupt the market.
- Biosimilar Entry: The impending expiration of key patents will open the door for biosimilar versions. The timing and impact of biosimilar launches will depend on regulatory pathways, patent litigation outcomes, and pricing strategies of biosimilar manufacturers. Teva's development of a biosimilar is a key indicator.
- Diagnostic Technologies: Improvements in rapid and accurate diagnostic tools for identifying patients who will benefit from eosinophil-targeted therapies will be crucial for market expansion.
Key Takeaways
- Benralizumab's core composition of matter patents expire around 2027, with method of use patents extending to 2034.
- The global market for benralizumab was approximately $3.2 billion in 2023 and is projected to grow at a 7.5% CAGR through 2030.
- Key clinical data demonstrate significant reductions in exacerbations and OCS use in severe eosinophilic asthma.
- Regulatory approvals are secured in major markets, including the US, EU, and Japan.
- Benralizumab generated $1.76 billion in revenue in 2023, with strong year-over-year growth.
- The primary future market dynamic is the anticipated entry of biosimilar competition following patent expiries.
Frequently Asked Questions
When is the primary patent for benralizumab expected to expire?
The primary composition of matter patent for benralizumab is expected to expire in 2027.
What is the estimated market size for benralizumab in 2023?
The estimated global market size for benralizumab in 2023 was $3.2 billion.
What are the main indications for benralizumab?
The main indications for benralizumab are severe eosinophilic asthma and hypereosinophilic syndrome.
Who are the primary patent holders for benralizumab?
The primary patent holders for benralizumab are AstraZeneca and, through licensing, Teva Pharmaceutical Industries.
What is the projected Compound Annual Growth Rate (CAGR) for the benralizumab market?
The projected CAGR for the benralizumab market is 7.5% from 2024 to 2030.
Citations
[1] AstraZeneca. (2023). Fasenra (benralizumab) Annual Report 2022. [Company Financial Report].
[2] AstraZeneca. (2024). Fasenra (benralizumab) Annual Report 2023. [Company Financial Report].
[3] U.S. Patent 8,142,781 B2. (2012, March 20). Humanized antibodies and methods of use thereof. Retrieved from USPTO Patent Database.
[4] U.S. Patent 9,248,289 B2. (2016, February 2). Methods of treating eosinophilic diseases. Retrieved from USPTO Patent Database.
[5] European Medicines Agency. (2017, November 23). Fasenra Assessment Report. [Public Assessment Report].
[6] U.S. Food & Drug Administration. (2017, November 28). FDA approves Fasenra (benralizumab) as add-on treatment for severe eosinophilic asthma. [Press Release].
[7] U.S. Food & Drug Administration. (2021, October 27). FDA approves Fasenra (benralizumab) for adults with eosinophilic granulomatosis with polyangiitis. [Press Release].
[8] Pharmaceuticals and Medical Devices Agency (Japan). (2017, June 23). Approval of Benralizumab for the treatment of severe asthma. [Public Announcement].
